Evaluation of treatment response and tissue necrosis as prognostic indicators following neoadjuvant chemoradiotherapy in rectal cancer patients
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: The objective of this study was to assess the prognostic roles of treatment response and tissue necrosis after chemoradiotherapy (CRT) in locally advanced rectal cancer. Methods: A total of 243 patients with locally advanced rectal cancer who underwent neoadjuvant CRT were included. Three treatment response groups were classified by their pathological stage results: complete treatment response (CTR), intermediate treatment response (ITR), and poor treatment response (PTR). Three tissue necrosis groups were classified based on tissue pathological results: complete necrosis response (CNR), intermediate necrosis response (INR), and poor necrosis response (PNR). Results: Overall survival (OS) and recurrence-free survival (RFS) rate at three years were 74.5% and 61.3%, respectively. The 3-year OS rates of the CTR, ITR, and PTR groups were 83.7%, 75.9%, and 69.7%, respectively (p < 0.001); the 3-year RFS rates were 76.7%, 69.0%, and 52.1%, respectively (p < 0.001). The 3-year OS rates of the CNR, INR, and PNR groups were 83.7%, 80.6%, and 61.8%, respectively (p < 0.001); the 3-year RFS rates were 76.7%, 68.9%, and 44.3%, respectively (p < 0.001). When compared to CTR/CNR, PTR/PNR was strongly related to an increased risk of recurrence (hazard ratio [HR], 5.53; 95% confidence interval [CI], 2.01 to 15.23 vs. HR, 6.37; 95% CI, 2.29 to 17.74, respectively) in univariate Cox regression. Both PTR and PNR were strongly associated with shorter RFS and OS when compared with CTR and CNR in the multivariate Cox regression. Conclusions: Tissue necrosis is an equally important prognostic marker as treatment response for oncologic outcomes in locally advanced rectal cancer.
Abstract
Background/Aims: The objective of this study was to assess the prognostic roles of treatment response and tissue necrosis after chemoradiotherapy (CRT) in locally advanced rectal cancer. Methods: A total of 243 patients with locally advanced rectal cancer who underwent neoadjuvant CRT were included. Three treatment response groups were classified by their pathological stage results: complete treatment response (CTR), intermediate treatment response (ITR), and poor treatment response (PTR). Three tissue necrosis groups were classified based on tissue pathological results: complete necrosis response (CNR), intermediate necrosis response (INR), and poor necrosis response (PNR). Results: Overall survival (OS) and recurrence-free survival (RFS) rate at three years were 74.5% and 61.3%, respectively. The 3-year OS rates of the CTR, ITR, and PTR groups were 83.7%, 75.9%, and 69.7%, respectively (p < 0.001); the 3-year RFS rates were 76.7%, 69.0%, and 52.1%, respectively (p < 0.001). The 3-year OS rates of the CNR, INR, and PNR groups were 83.7%, 80.6%, and 61.8%, respectively (p < 0.001); the 3-year RFS rates were 76.7%, 68.9%, and 44.3%, respectively (p < 0.001). When compared to CTR/CNR, PTR/PNR was strongly related to an increased risk of recurrence (hazard ratio [HR], 5.53; 95% confidence interval [CI], 2.01 to 15.23 vs. HR, 6.37; 95% CI, 2.29 to 17.74, respectively) in univariate Cox regression. Both PTR and PNR were strongly associated with shorter RFS and OS when compared with CTR and CNR in the multivariate Cox regression. Conclusions: Tissue necrosis is an equally important prognostic marker as treatment response for oncologic outcomes in locally advanced rectal cancer.
참고문헌 (18)
- Kockerling F, "Influence of surgery on metachronous distant metastases and survival in rectal cancer", J Clin Oncol, 16, pp.324~329 (1998)
- Nuyttens JJ, "The influence of small bowel motion on both a conventional three-field and intensity modulated radiation therapy (IMRT) for rectal cancer", Cancer Radiother, 8, pp.297~304 (2004)
- Arbea L, "Intensity-modulated radiation therapy (IMRT) vs. 3D conformal radiotherapy (3DCRT) in locally advanced rectal cancer (LARC): dosimetric comparison and clinical implications", Radiat Oncol, 5, pp.17~ (2010)
- Samuelian JM, "Reduced acute bowel toxicity in patients treated with intensity-modulated radiotherapy for rectal cancer", Int J Radiat Oncol Biol Phys, 82, pp.1981~1987 (2012)
- O’Connell JB, "Are survival rates different for young and older patients with rectal cancer?", Dis Colon Rectum, 47, pp.2064~2069 (2004)
- Rodel C, "Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO", ARO, Lancet Oncol, pp.2012, 13[DOI]
- Chua YJ, "Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial", Lancet Oncol, 11, pp.241~248 (2010)
- Klautke G, "Intensified concurrent chemoradiotherapy with 5-fluorouracil and irinotecan as neoadjuvant treatment in patients with locally advanced rectal cancer", Br J Cancer, 92, pp.1215~1220 (2005)
- Silberfein EJ, "Long-term survival and recurrence outcomes following surgery for distal rectal cancer", Ann Surg Oncol, 17, pp.2863~2869 (2010)
- Park IJ, "Neoadjuvant treatment response as an early response indicator for patients with rectal cancer", J Clin Oncol, 30, pp.1770~1776 (2012)
- Rodel C, "Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer", J Clin Oncol, 23, pp.8688~8696 (2005)
- Maas M, "Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data", Lancet Oncol, 11, pp.835~844 (2010)
- Santos MD, "Prognostic value of mandard and dworak tumor regression grading in rectal cancer: study of a single tertiary center", ISRN Surg, 2014, pp.310542~ (2014)
- Capirci C, "Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients", Int J Radiat Oncol Biol Phys, 72, pp.99~107 (2008)
- Breugom AJ, "The value of adjuvant chemotherapy in rectal cancer patients after preoperative radiotherapy or chemoradiation followed by TME-surgery: the PROCTOR", SCRIPT study, 2013, pp.49(Suppl 3), S1~
- Cionini L, "Final results of randomized trial on adjuvant chemotherapy after preoperative chemoradiation in rectal cancer", Radiother Oncol, 96(Suppl 1), pp.S113~S114 (2010)
- Bosset JF, "Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study", Lancet Oncol, 15, pp.184~190 (2014)
- Hong YS, "Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial", Lancet Oncol, 15, pp.1245~1253 (2014)